Evaluation in vinyl chloride monomer (VCM)-exposed workers and the relationship between liver lesions and gene polymorphisms of metabolic enzymes

Table 1 Prevalence of symptoms and signs between exposure and control groups

0.42 (0.20-0.88)Symptoms and signs	Exposure group )	Control group	Relative risk (RR
	n = 238(%)	n = 212(%)
Neurastheniaa	40 (16.81)	21 (9.91)	1.74 (1.06-2.58)
Pharyngeal irritationb	138 (57.98)	63 (29.72)	1.97 (1.56-2.48)
Abnormal ECGa	24 (10.08)	40 (18.87)	0.51 (0.32-0.83)
Cholelithiasis	6 (2.52)	7 (3.30)	0.76 (0.26-2.24)
Renal cyst	2 (0.84)	3 (1.42)	0.59 (0.10-3.52)
Liver ultrasonography abnormalityb	51 (21.41)	5 (2.36)	10.69 (4.38-26.12)
Fatty livera	10 (4.20)	21 (9.91)	0.42 (0.20-0.88)
Hemoglobin disordersa	46 (19.33)	22 (10.38)	2.07 (1.20-3.57)
Hypertension	11 (4.62)	15 (7.07)	0.64 (0.29-1.42)
Hepatic hemangioma	3 (1.26)	3 (1.42)	0.89 (0.18-4.37)
Leucopenia	4 (1.68)	1 (0.47)	3.61 (0.40-32.53)

^aP < 0.05 vs control group;

^bP < 0.01 vs control group.